RECOGNISE, REFER URGENTLY FOR STAGING AND TREATMENT (RECOGNITION & REFERRAL)
Primary malignancy of the bronchus, lung or trachea, strongly linked to smoking. The definitive management depends on cell type and stage and it belongs to a lung-cancer multidisciplinary team. In stage 1 non-small cell disease the article puts surgery at the centre, the operation being a lobectomy or a pneumonectomy with sampling of the mediastinal lymph nodes; at stage II it prefers surgery with chemotherapy afterwards. Stage IV it calls incurable, the aim there being longer survival and lighter symptoms rather than cure, with every advanced non-small cell tumour checked for the mutations that have a matching inhibitor. Small cell disease responds strongly to chemotherapy but recurs often, and is treated according to its stage. Refer urgently for imaging, tissue diagnosis and oncology assessment. - Refer, with advice
Children follow the same pathway: recognise and refer. No primary-care medicine is implied.
No dose - referral pathway, no medicine given in primary care
Primary malignancy of the bronchus, lung or trachea, strongly linked to smoking. The definitive management depends on cell type and stage and it belongs to a lung-cancer multidisciplinary team. In stage 1 non-small cell disease the article puts surgery at the centre, the operation being a lobectomy or a pneumonectomy with sampling of the mediastinal lymph nodes; at stage II it prefers surgery with chemotherapy afterwards. Stage IV it calls incurable, the aim there being longer survival and lighter symptoms rather than cure, with every advanced non-small cell tumour checked for the mutations that have a matching inhibitor. Small cell disease responds strongly to chemotherapy but recurs often, and is treated according to its stage. Refer urgently for imaging, tissue diagnosis and oncology assessment.
- RED FLAG - Malignant spinal cord compression or brain metastasis (new focal neurological deficit, severe unremitting back pain with leg weakness): assess urgently and refer.
- RED FLAG - Superior vena cava syndrome (dilated neck veins, facial/neck/upper-limb edema, plethora) is a distinct emergency presentation of lung cancer.
- There is no drug row on this card and that is a finding, not a gap. Every drug this article names - platinum chemotherapy, the EGFR and ALK tyrosine kinase inhibitors, the PD-1 and PD-L1 antibodies, bevacizumab - is systemic cytotoxic or targeted oncology therapy, dosed by body surface area, mutation status and blood counts by an oncologist. This app does not dose systemic cancer therapy for anyone, and the article states no dose for any of them.
- Symptom relief in advanced disease is delivered by oncology and palliative care, and the article's own tools for it are not prescriptions. Chemotherapy eases pain and cough and may extend survival; palliative radiotherapy relieves symptoms in 41% to 95% of patients with lung cancer, and is central to controlling the pain of metastasis, brain and bone especially. Where the airway is obstructed - and the article puts central airway occlusion at almost 30% of lung cancer patients - bronchoscopic laser destruction with a stent afterwards gives immediate relief. (Lung Cancer - StatPearls - NCBI Bookshelf, NBK482357)
- The one intervention that IS yours, at every single visit. The article makes stopping smoking the most important preventive measure there is, for everyone, and asks that the link between smoking and lung cancer be put to the patient at every visit. (Lung Cancer - StatPearls - NCBI Bookshelf, NBK482357) It names no drug for it - the regimens are listed under Smoking Cessation.
- RED FLAG - Haemoptysis, unexplained weight loss with a persistent cough, or new hoarseness or chest pain lasting several weeks, especially in a smoker.